M2-β2 interaction: A basis for combined bronchodilator treatment;Interacción M2-β2: Bases para el tratamiento broncodilatador combinado

Archivos de Bronconeumologia

Volumn 49, Issue 7, 2013, Pages 279-281

  López Campos, José Luis ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LONG ACTING DRUG; MUSCARINIC M2 RECEPTOR AGONIST;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ANTAGONISM; HUMAN;

ADENYLATE CYCLASE; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; CALCIUM SIGNALING; CYCLIC AMP; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MUSCARINIC ANTAGONISTS; MUSCLE, SMOOTH; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; RECEPTORS, ADRENERGIC, BETA-2; SCOPOLAMINE DERIVATIVES; SECOND MESSENGER SYSTEMS;

EID: 84879463930     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2012.10.001     Document Type: Article

References (19)

1. Malerba M., Radaeli A., Morjaria J.B. Therapeutic potential for novel ultra long-acting beta2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today 2012, 17:496-504.
2. Matera M.G., Page C.P., Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011, 32:495-506.
3. Van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Zaagsma J., Mueller A., et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010, 104:995-1004.
4. Mahler D.A., D'Urzo A., Bateman E.D., Ozkan S.A., White T., Peckitt C., et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012, 67:781-788.
5. Van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
6. Miles M.C., Donohue J.F., Ohar J.A. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?. Drugs 2012, 72:301-308.
7. Van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012, 21:101-108.
8. Disse B., Reichl R., Speck G., Traunecker W., Ludwig Rominger K.L., Hammer R. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 1993, 52:537-544.
9. Spengler C.M., Shea S.A. Endogenous circadian rhythm of pulmonary function in healthy humans. Am J Respir Crit Care Med 2000, 162:1038-1046.
10. Calverley P.M., Lee A., Towse L., van Noord J., Witek T.J., Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003, 58:855-860.
11. Magnussen H., Verkindre C., Jack D., Jadayel D., Henley M., Woessner R., et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010, 104:1869-1876.
12. Terzano C., Petroianni A., Conti V., Ceccarelli D., Graziani E., Sanduzzi A., et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008, 102:1701-1707.
13. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459:356-363.
14. Caulfield M.P., Birdsall N.J. International Union of Pharmacology. xvii. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998, 50:279-290.
15. Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:297-304.
16. Roffel A.F., Elzinga C.R., Van Amsterdam R.G., De Zeeuw R.A., Zaagsma J. Muscarinic M2 receptors in bovine tracheal smooth muscle: discrepancies between binding and function. Eur J Pharmacol 1988, 153:73-82.
17. Torphy T.J. Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol Sci 1994, 15:370-374.
18. Kerwin E.M., D'Urzo A.D., Gelb A.F., Lakkis H., Garcia Gil E., Caracta C.F., et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012, 9:90-101.
19. D'Urzo A., Ferguson G.T., van Noord J.A., Hirata K., Martin C., Horton R., et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:156.